These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32777170)

  • 1. Cyclosporine and COVID-19: Risk or favorable?
    Poulsen NN; von Brunn A; Hornum M; Blomberg Jensen M
    Am J Transplant; 2020 Nov; 20(11):2975-2982. PubMed ID: 32777170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir.
    Pawlotsky JM
    Clin Infect Dis; 2020 Nov; 71(16):2191-2194. PubMed ID: 32409832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?
    Rodriguez-Cubillo B; de la Higuera MAM; Lucena R; Franci EV; Hurtado M; Romero NC; Moreno AR; Valencia D; Velo M; Fornie IS; Sanchez-Fructuoso AI
    Am J Transplant; 2020 Nov; 20(11):3173-3181. PubMed ID: 32529737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVID-19 pandemic: A community approach.
    Cravedi P; Schold JD; Safa K; Kates OS; Elfadawy N; Mannon RB; Shah MB; Hammond SP; Avery R; Guerrero Miranda C; Riella LV; Jowsey-Gregoire S; Akalin E; Camirand G; Alegre ML; Azzi J
    Clin Transplant; 2020 Nov; 34(11):e14059. PubMed ID: 32762055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV2 and immunosuppression: A double-edged sword.
    Lai Q; Spoletini G; Bianco G; Graceffa D; Agnes S; Rossi M; Lerut J
    Transpl Infect Dis; 2020 Dec; 22(6):e13404. PubMed ID: 32639598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
    Muralidar S; Ambi SV; Sekaran S; Krishnan UM
    Biochimie; 2020 Dec; 179():85-100. PubMed ID: 32971147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience.
    Bossini N; Alberici F; Delbarba E; Valerio F; Manenti C; Possenti S; Econimo L; Maffei C; Pola A; Terlizzi V; Salviani C; Moscato M; Pasquali S; Zambetti N; Tonoli M; Affatato S; Pecchini P; Viola FB; Malberti F; Depetri G; Gaggiotti M; Scolari F;
    Am J Transplant; 2020 Nov; 20(11):3019-3029. PubMed ID: 32627319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London.
    Vaid N; Ardissino M; Reed TAN; Goodall J; Utting P; Miscampbell M; Condurache DG; Cohen DL
    J Intern Med; 2021 Mar; 289(3):385-394. PubMed ID: 32902028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.
    Johnson KM; Belfer JJ; Peterson GR; Boelkins MR; Dumkow LE
    Pharmacotherapy; 2020 Jun; 40(6):517-524. PubMed ID: 32339304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rate of COVID-19 pneumonia in kidney transplant recipients-A battle between infection and immune response?
    Ghaffari Rahbar M; Nafar M; Khoshdel A; Dalili N; Abrishami A; Firouzan A; Poorrezagholi F; Samadian F; Ziaie S; Fatemizadeh S; Samavat S
    Transpl Infect Dis; 2020 Oct; 22(5):e13406. PubMed ID: 32654357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
    Goldman JD; Robinson PC; Uldrick TS; Ljungman P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.